Satellos Bioscience (TSE:MSCL) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Satellos Bioscience successfully closed a $40 million public offering, issuing over 63 million equity securities, to fund its Phase 2 clinical program for SAT-3247. The offering was led by Bloom Burton Securities Inc. and participated by several agents. The funds will support clinical development and general corporate needs.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.